BeiGene Deferred Long Term Liab from 2010 to 2024
| BGNE Stock | USD 215.00 8.84 4.29% |
Deferred Long Term Liabilities | First Reported 2014-12-31 | Previous Quarter 14.7 M | Current Value 15.2 M | Quarterly Volatility 8 M |
Check BeiGene financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BeiGene's main balance sheet or income statement drivers, such as Depreciation And Amortization of 92.1 M, Interest Expense of 39.2 M or Selling General Administrative of 1.5 B, as well as many indicators such as Price To Sales Ratio of 7.27, Dividend Yield of 0.0 or PTB Ratio of 4.02. BeiGene financial statements analysis is a perfect complement when working with BeiGene Valuation or Volatility modules.
BeiGene | Deferred Long Term Liab |
Latest BeiGene's Deferred Long Term Liab Growth Pattern
Below is the plot of the Deferred Long Term Liab of BeiGene over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. BeiGene's Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BeiGene's overall financial position and show how it may be relating to other accounts over time.
| Deferred Long Term Liab | 10 Years Trend |
|
Deferred Long Term Liab |
| Timeline |
BeiGene Deferred Long Term Liab Regression Statistics
| Arithmetic Mean | 7,796,055 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 98.63 | |
| Mean Deviation | 6,613,651 | |
| Median | 10,067,475 | |
| Standard Deviation | 7,689,291 | |
| Sample Variance | 59.1T | |
| Range | 24.8M | |
| R-Value | 0.70 | |
| Mean Square Error | 32.2T | |
| R-Squared | 0.49 | |
| Significance | 0 | |
| Slope | 1,208,673 | |
| Total Sum of Squares | 827.8T |
BeiGene Deferred Long Term Liab History
About BeiGene Financial Statements
BeiGene stakeholders use historical fundamental indicators, such as BeiGene's Deferred Long Term Liab, to determine how well the company is positioned to perform in the future. Although BeiGene investors may analyze each financial statement separately, they are all interrelated. For example, changes in BeiGene's assets and liabilities are reflected in the revenues and expenses on BeiGene's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in BeiGene. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Deferred Long Term Liabilities | 16.3 M | 10.1 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether BeiGene is a strong investment it is important to analyze BeiGene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact BeiGene's future performance. For an informed investment choice regarding BeiGene Stock, refer to the following important reports:Check out the analysis of BeiGene Correlation against competitors. For information on how to trade BeiGene Stock refer to our How to Trade BeiGene Stock guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BeiGene. If investors know BeiGene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BeiGene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.19) | Revenue Per Share 225.239 | Quarterly Revenue Growth 0.395 | Return On Assets (0.1) | Return On Equity (0.23) |
The market value of BeiGene is measured differently than its book value, which is the value of BeiGene that is recorded on the company's balance sheet. Investors also form their own opinion of BeiGene's value that differs from its market value or its book value, called intrinsic value, which is BeiGene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BeiGene's market value can be influenced by many factors that don't directly affect BeiGene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BeiGene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BeiGene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BeiGene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.